The business objective of TregTherapeutics, Inc is to expedite the availability of the TILAC platform across the spectrum of autoimmune applications.
The technology is applicable to dozens of autoimmune diseases, as well as, numerous other inflammatory conditions. The broad application of this technology, with roots deeply embedded in the treatment of multiple sclerosis, is based on commonality found within the basic communication machinery of the immune system. TregTherapeutics’ management recognizes the importance of focusing financial, technical, and time resources on a critical path, and has developed strategic and tactical elements into a plan that can bring the technology into the clinic smoothly and quickly.
Management’s immediate tactical objective, then, is clear: complete proof-of-concept in humans in a representative autoimmune disease that can demonstrate safety and efficacy. Resources are currently being assembled to proceed with these first-in-human studies embodied by this objective.
The acquisition of funding to enable the execution of this chosen pathway is our highest priority. We are currently pursuing equity funding and are interested in establishing relationships with individual investors, venture capital firms, or appropriate pharmaceutical / biotech companies. Interested investors are urged to contact us for further information.